Solifenacin treatment in men with overactive bladder: Effects on symptoms and patient-reported outcomes

Aging Male

Volumn 13, Issue 2, 2010, Pages 100-107

  Kaplan, Steven A ^a   Goldfischer, Evan R ^b   Steers, William D ^c   Gittelman, Marc ^d   Andoh, Masakazu ^e,g   Forero Schwanhaeuser, Sergio ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Hudson Valley Urology   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d South Florida Medical Research   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f GLAXOSMITHKLINE   (United States)

^g RHO INC   (United States)

Author keywords

Male; Muscarinic antagonists; Overactive; Treatment outcome; Urinary bladder

Indexed keywords

SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOM; TREATMENT DURATION;

AGED; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 77951835413     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685530903440408     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. (Pubitemid 34195211)
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293.
3. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-659.
4. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50: 1306-1315. (Pubitemid 44692945)
5. Miner MM. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ? Curr Urol Rep 2009;10:254-260.
6. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 2008;54:543-562.
7. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006;68 (2 Suppl) :38-48. (Pubitemid 44189489)
8. Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006;50:675-683. (Pubitemid 44332687)
9. Kaplan SA. New data on tolterodine: do recent findings dispel questions about treating overactive bladder in men? Eur Urol Suppl 2007;6:10-16.
10. Garely AD, Kaufman JM, Sand PK, Smith N, Masakazu A. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare open-label trial (VOLT). Clin Ther 2006;28:1935-1946. (Pubitemid 46043507)
11. Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramee C, Capo JP, Jr., Seifeldin R, Forero-Schwanhaeuser S, Nandy I. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexibledose study. Clin Ther 2008;30:1766-1781.
12. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC) : a singleitem global measure for patients with overactive bladder. Eur Urol 2006;49:1079-1086. (Pubitemid 43673993)
13. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-574. (Pubitemid 34876130)
14. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006;176:627-632; discussion 632. (Pubitemid 43927875)
15. Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008;180:1034-1041.
16. Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2008;28:52-57.
17. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73:14-18.
18. Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-1064. (Pubitemid 46281419)
19. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-332. (Pubitemid 44175507)
20. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008;28:356-365. (Pubitemid 351328908)
21. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273-2275. (Pubitemid 41611800)
22. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175 (3 Part 1) :999-1004. (Pubitemid 43200054)
23. Dahm TL, Ostri P, Kristensen JK, Walter S, Frimodt-Moller C, Rasmussen RB, Nohr M, Alexander N. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Urol Int 1995;55:205-208.
24. Kershen RT. Algorithms for the management of overactive bladder. Curr Urol Rep 2009;10:352-361.
25. Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, Lee HJ, Choe G, Hong SK. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology 2008;71:395-398. (Pubitemid 351374707)
26. Mao Q, Zheng X, Wang Y, Qin J, Yang K, Bai Y, Xie L. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Neph 2009 Feb. 18 [Epub ahead of print].
27. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72: 1061-1067.
28. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009;55:472-479.
29. MacDiarmid S, Rogers A. Male overactive bladder: the role of urodynamics and anticholinergics. Curr Urol Rep 2007; 8:66-73.(Pubitemid 46202661)